14.1 Acute Respiratory Distress: Asthma, COPD, Pulmonary Edema & Anaphylaxis

14.1 Acute Respiratory Distress: Asthma, COPD, Pulmonary Edema & Anaphylaxis

Pathophysiology of Lower Airway Obstruction

Acute respiratory distress is one of the most frequent and time-critical presentations encountered in Canadian primary care paramedic practice. Under the Canadian Paramedic Competence Framework (CPCF Appendix A #4, #7, #32), paramedics must rapidly identify the physiological mechanism underlying respiratory failure, differentiate reactive bronchospastic disorders from alveolar fluid extravasation, and administer targeted pharmacotherapy.

Lower airway obstruction in disorders such as acute asthma and Chronic Obstructive Pulmonary Disease (COPD) exacerbations is characterized by a classical pathological triad:

1. Bronchospasm: Hyperreactive bronchial smooth muscle contraction narrowing the lumen of the conducting bronchioles. This increases airway resistance exponentially according to Poiseuille's law, where airway resistance is inversely proportional to the fourth power of the airway radius (Resistance proportional to 1/radius^4).
2. Mucosal Edema: Eosinophilic and neutrophilic inflammatory cascades cause capillary hyperpermeability within the bronchial submucosa, producing profound wall thickening that further encroaches upon the lumen.
3. Hypersecretion & Mucus Plugging: Goblet cell hyperplasia and submucosal gland hyperactivity generate thick, tenacious secretions that overwhelm the impaired mucociliary escalator, creating widespread mechanical plugging of peripheral terminal airways.

During expiration, dynamic intrathoracic pressure compresses the already narrowed airways, trapping air within the distal alveoli. This leads to alveolar hyperinflation (auto-PEEP), ventilation-perfusion (V/Q) mismatch, elevated work of breathing, and eventual diaphragmatic fatigue resulting in acute hypercapnic and hypoxemic respiratory failure.

---

Differentiating Obstructive Exacerbations vs Cardiogenic Pulmonary Edema vs Pneumonia

Accurate clinical differentiation is vital because administering high-volume fluid resuscitation or incorrect respiratory therapies can precipitate fatal decompensation. Paramedics systematically synthesize history, physical examination, auscultation, and continuous capnography.

[!IMPORTANT] The Capnographic 'Shark Fin': In obstructive airway diseases (asthma and COPD), bronchospasm causes heterogeneous emptying of alveoli across lung units with variable time constants. The continuous waveform capnography display loses its crisp rectangular 90-degree angle; Phase II ascends slowly and Phase III displays a marked upward slope, creating the diagnostic 'shark fin' morphology. In pure cardiogenic pulmonary edema, alveoli empty synchronously despite interstitial/alveolar fluid, maintaining an upright rectangular waveform.

---

Prehospital Pharmacotherapy for Obstructive Airway Disease

Canadian paramedic protocols utilize a synergistic combination of beta-2 adrenergic agonists and anticholinergic agents to achieve rapid bronchodilation and reduce airway resistance.

1. Salbutamol (Ventolin)

• Class & Receptor Mechanism: Selective short-acting beta-2 adrenergic receptor agonist. Binding to beta-2 receptors on bronchial smooth muscle activates intracellular adenylyl cyclase, which converts ATP to cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA), inhibiting myosin light-chain kinase and sequestering intracellular calcium, producing rapid bronchial smooth muscle relaxation.
• Prehospital Dosing:
  • Nebulized: 2.5 mg to 5.0 mg in 2.5–3.0 mL normal saline driven by oxygen at 6–8 L/min.
  • Metered Dose Inhaler (MDI): 4 to 8 puffs (100 mcg/puff) administered via a spacer device, delivering 1 puff every 30–60 seconds with 4–5 normal tidal breaths per puff.
• Adverse Effects: Reflex tachycardia (peripheral vasodilation and modest beta-1 crossover), skeletal muscle tremors, transient hypokalemia (intracellular potassium shifting), and transient hypoxemia due to beta-2 pulmonary vasodilation preceding full bronchodilation.

2. Ipratropium Bromide (Atrovent)

• Class & Receptor Mechanism: Quaternary ammonium anticholinergic (parasympatholytic) agent. It competitively antagonizes muscarinic acetylcholine receptors (specifically M3 receptors) on bronchial smooth muscle and submucosal seromucous glands. This blocks acetylcholine-mediated bronchoconstriction and reflex vagal tone while curtailing excessive mucus secretion.
• Prehospital Dosing: 500 mcg (0.5 mg) nebulized, routinely combined with salbutamol ('Combivent') in the initial nebulizer chamber.
• Clinical Nuance: Ipratropium has a slower onset (15–30 minutes) than salbutamol (5 minutes) but provides sustained, synergistic bronchodilation. In prehospital protocols, ipratropium is typically administered once or twice in the acute phase, whereas salbutamol can be repeated continuously or back-to-back.

3. Epinephrine in Status Asthmaticus

When a patient with acute severe asthma fails to respond to inhaled bronchodilators, develops profound exhaustion, exhibits a 'silent chest' (absence of wheezing due to negligible airflow), or experiences impending respiratory arrest, systemic epinephrine is indicated under CPCF Appendix A #32.

• Formulation & Route: Epinephrine 1:1,000 (1 mg/mL) administered strictly Intramuscularly (IM) into the anterolateral mid-thigh.
• Adult Dose: 0.3 mg to 0.5 mg IM.
• Pediatric Dose: 0.01 mg/kg IM (maximum single dose 0.3 mg).
• Mechanism: Provides intense beta-2 mediated bronchodilation while simultaneously exerting alpha-1 mediated vasoconstriction to shrink mucosal edema in airways that inhaled aerosols cannot reach due to critical mechanical occlusion.

---

Systemic Anaphylaxis: Diagnostic Criteria & Resuscitation

Anaphylaxis is an acute, life-threatening multi-system hypersensitivity reaction triggered by IgE-mediated mast cell and basophil degranulation (or non-IgE direct activation). Massive release of preformed histamine, leukotrienes (LTC4, LTD4, LTE4), prostaglandins, and platelet-activating factor (PAF) precipitates systemic vasodilation, profound capillary permeability, mucosal angioedema, and intense smooth muscle bronchoconstriction.

Clinical Diagnostic Criteria

Anaphylaxis is highly likely when any one of the following three clinical presentations occurs following allergen exposure:

1. Acute onset (minutes to several hours) involving skin/mucosal tissue (generalized hives, pruritus, flushing, swollen lips/tongue/uvula) PLUS AT LEAST ONE of the following:
   • Respiratory compromise: Dyspnea, wheezing, stridor, hypoxemia, reduced peak expiratory flow.
   • Cardiovascular compromise: Reduced blood pressure (SBP <90 mmHg or >30% drop from baseline) or associated end-organ dysfunction (syncope, hypotonia, incontinence).
2. Two or more of the following occurring rapidly after exposure to a likely allergen:
   • Involvement of skin/mucosal tissue (urticaria, angioedema, flushing).
   • Respiratory compromise (dyspnea, bronchospasm, stridor).
   • Reduced blood pressure or associated symptoms of shock.
   • Persistent gastrointestinal symptoms (cramping abdominal pain, repetitive vomiting, diarrhea).
3. Reduced blood pressure alone after exposure to a known allergen for that specific patient (adult SBP <90 mmHg or >30% decrease from baseline).

Anaphylaxis Immediate Resuscitation Sequence:
1. Discontinue offending trigger (e.g., stop medication infusion, scrape honeybee stinger).
2. First-Line Pharmacotherapy: Epinephrine 1:1,000 IM (0.3–0.5 mg adult; 0.01 mg/kg ped) in vastus lateralis.
3. Position patient supine with legs elevated (do NOT allow patient to suddenly stand or sit upright).
4. High-flow oxygen via non-rebreather mask (12–15 L/min) to maintain SpO2 >94%.
5. Aggressive Volume Resuscitation: Large-bore IV access; 1–2 L isotonic crystalloid (normal saline) bolus.
6. Secondary Pharmacotherapy: Diphenhydramine 25–50 mg IV/IM, nebulized salbutamol for persistent bronchospasm.
7. Repeat Epinephrine IM every 5 to 15 minutes if respiratory distress or hypotension persists.

The Mandatory First-Line Role of Intramuscular Epinephrine

Epinephrine is the only medication proven to reduce mortality in anaphylaxis. It is the undisputed first-line intervention:

• Alpha-1 agonism: Reverses systemic arteriolar vasodilation, increases systemic vascular resistance (SVR), restores mean arterial pressure, and halts capillary leakage to relieve laryngeal edema.
• Beta-2 agonism: Relaxes bronchial smooth muscle to relieve bronchospasm and stabilizes mast cell membranes, shutting down further mediator exocytosis.
• Injection Site: The anterolateral mid-thigh (vastus lateralis) must always be used. Intramuscular injection into the thigh achieves peak therapeutic plasma concentrations in 8 minutes, compared to over 30 minutes for subcutaneous or deltoid injections.

Aggressive Fluid Challenges in Anaphylactic Distributive Shock

Anaphylactic shock is a mixed distributive and hypovolemic shock. Up to 35% of the total circulating intravascular blood volume can extravasate into the interstitial third space within 10 minutes due to massive post-capillary venular fenestration. Concurrently, profound venous pooling collapses cardiac preload. Paramedics must establish two large-bore IVs and rapidly infuse 1 to 2 litres of normal saline (20 mL/kg in pediatrics) under pressure to restore effective circulating volume. Epinephrine cannot maintain perfusion if the venous vascular tree is completely empty.

Secondary Medications: Role and Limitations

• Diphenhydramine (Benadryl): Dose: 25 mg to 50 mg IV or IM. Competitive histamine H1 receptor antagonist. It relieves cutaneous pruritus, flushing, and urticaria. Critical Pearl: Diphenhydramine does NOT reverse laryngeal edema, does not alleviate bronchospasm, and does not treat hypotension. It must never delay or substitute for epinephrine.
• Inhaled Beta-2 Agonists: Salbutamol 2.5–5.0 mg nebulized is indicated as an adjunct for persistent lower airway wheezing refractory to initial IM epinephrine.

---

Clinical Scenario: Refractory Status Asthmaticus in a Young Adult

Paramedics are dispatched priority code 4 to a 22-year-old female with acute severe asthma. Bystanders report the patient has used her rescue inhaler over 20 times during the past 4 hours without relief.

1. Initial Assessment: The patient is sitting in a severe tripod position, unable to speak full syllables, with profound intercostal and sternocleidomastoid retractions. Skin is pale and diaphoretic. Vital signs: HR 142 bpm, RR 36/min, BP 138/88 mmHg, SpO2 86% on room air.
2. Auscultation & Capnography: Auscultation reveals a near 'silent chest' with faint, high-pitched wheezes at the apices and absent breath sounds at the bases. Continuous waveform capnography demonstrates a severe 'shark fin' morphology with an ETCO2 of 54 mmHg, reflecting progressive alveolar hypoventilation and air trapping.
3. Immediate Interventions: Paramedic 1 initiates continuous high-flow oxygen via a nebulizer mask charged with salbutamol 5.0 mg and ipratropium bromide 500 mcg. Paramedic 2 recognizes the silent chest and acute exhaustion as indicators of impending respiratory arrest.
4. Systemic Bronchodilation: Paramedic 2 immediately administers Epinephrine 1:1,000 (0.4 mg) IM into the left vastus lateralis muscle.
5. Reassessment & Transport: Within 6 minutes of IM epinephrine and continuous nebulization, breath sounds improve from silent to loud, bilateral expiratory wheezes, reflecting re-established tidal airflow. SpO2 rises to 93% on oxygen, and ETCO2 decreases to 44 mmHg. A second dose of nebulized salbutamol (2.5 mg) is delivered en route, and the patient arrives at the emergency department stabilized.

---

Exam Pitfalls & High-Yield Respiratory Pearls

• The 'Silent Chest' Trap: A patient who previously had loud wheezing but now presents with an auscultatorily silent chest and lethargy has not improved; they have reached critical airway closure and exhaustion, requiring immediate IM epinephrine and assisted ventilation.
• Delaying Epinephrine for Antihistamines: Never administer diphenhydramine before epinephrine in anaphylaxis. Every minute of delay in administering IM epinephrine increases the incidence of hypoxic brain death and biphasic fatal arrest.
• Positioning Hazards in Anaphylaxis: Placing an anaphylactic patient into an upright sitting or standing position can precipitate the 'empty ventricle syndrome'—sudden total collapse of venous return causing instantaneous pulseless electrical activity (PEA) arrest. Keep patients strictly supine or in recovery position with legs elevated unless severe airway compromise mandates a semi-seated posture.
• Shark Fin Capnography: Memorize that sloped Phase III capnography indicates lower airway obstruction (asthma, COPD), while flat rectangular Phase III indicates cardiogenic pulmonary edema or normal physiology.